Treatment of acute coronary syndrome with GLP-1

• US 7,056,887 B2
• Filed: 12/18/2002
• Issued: 06/06/2006
• Est. Priority Date: 05/19/2000
• Status: Expired due to Term

• Current Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Coolidge, Thomas R., Ehlers, Mario
• Primary Examiner(s): Wax, Robert A.
• Assistant Examiner(s): Kosson, Rosanne
• Application Number:
  US10/322,839
• Publication Number:
  US 20040002454A1
• Time in Patent Office: 1,266 Days
• Field of Search: 514/12, 514/2, 424/542, 530/324
• US Class Current: 514/6.9
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of an exendin-4 molecule. The exendin-4 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.

Claims

1. A method of treating a patient suffering from acute coronary syndrome, comprising administering to the patient a therapeutically effective amount of an exendin-4.

2. The method of claim 1, wherein the exendin is administered in at least one dose.

3. The method of claim 1, wherein the exendin is administered continuously.

4. The method of claim 1, wherein glucose, a potassium salt, or a combination thereof, is co-administered with the exendin.

5. The method of claim 1, wherein said patient has a condition selected from the group consisting of unstable angina, non-Q-wave cardiac necrosis, Q-wave myocardial infarction, acute myocardial infarction, ischemic heart disease, and stable angina.

6. The method of claim 1, wherein the patient has a blood troponin I level of no more than 0.4 ng/ml.

7. The method of claim 1, wherein the patient has a blood troponin T level of no more than 0.1 ng/ml.

8. The method of claim 1, wherein the patient does not have elevated blood creatine kinase.

9. The method of claim 1, wherein the patient does not have ST-segment elevation.

10. The method of claim 1, wherein the patient does not exhibit a pathological Q-wave.

11. The method according to claim 1, wherein said patient exhibits one or more of the following symptoms:

chest pain greater than 15 minutes in duration, chest pain at rest, chest pain following minimal exertion that is poorly responsive to sublingual nitrates.

12. The method according to claim 1, wherein said patient self-administers the exendin.